Alkylating agents showed no clear difference in adverse effects: serum creatinine compared with cyclosporin (low certainty).
The review found no eligible studies for this question.
Alkylating agents may leads to lower adverse effects: hypertrichosis compared with cyclosporin (low certainty).
Alkylating agents may leads to lower adverse effects: gum hypertrophy compared with cyclosporin (low certainty).
It is very uncertain whether alkylating agents changes adverse effects: hypertension compared with cyclosporin (very low certainty).
It is very uncertain whether alkylating agents changes adverse effects: leucopenia compared with cyclosporin (very low certainty).
Alkylating agents probably leads to lower relapse at 6 to 12 months compared with steroids, placebo or both (moderate certainty).
The review found no eligible studies for this question.
The review found no eligible studies for this question.
Alkylating agents led to higher CPA: leucopenia compared with steroids, placebo or both; GRADE not reported.
Alkylating agents showed no clear difference in chlorambucil: leucopenia compared with steroids, placebo or both; GRADE not reported.
Rituximab may leads to higher adverse effects: moderate to severe Infusion reactions compared with placebo or control (low certainty).
Intravenous may leads to lower relapse at 6 months compared with oral cyclophosphamide (low certainty).
Intravenous may leads to lower continuing frequently‐relapsing or steroid‐dependent SSNS at 6 months compared with oral cyclophosphamide (low certainty).
Intravenous showed no clear difference in relapse at end of study compared with oral cyclophosphamide (low certainty).
The review found no eligible studies for this question.
Intravenous showed no clear difference in adverse events: leucopenia compared with oral cyclophosphamide (low certainty).
Intravenous showed no clear difference in adverse events: hair loss compared with oral cyclophosphamide (low certainty).
Intravenous may leads to lower adverse events: all infections compared with oral cyclophosphamide (low certainty).
It is very uncertain whether intravenous changes adverse events: nausea and vomiting compared with oral cyclophosphamide (very low certainty).